Search Results - "Yood, Robert"

Patients' knowledge and beliefs concerning gout and its treatment: a population based study by Harrold, Leslie R, Mazor, Kathleen M, Peterson, Daniel, Naz, Nausheen, Firneno, Cassandra, Yood, Robert A

“…For patients to effectively manage gout, they need to be aware of the impact of diet, alcohol use, and medications on their condition. We sought to examine…”
Get full text

Efficacy and Tolerability of Pegloticase for the Treatment of Chronic Gout in Patients Refractory to Conventional Treatment: Two Randomized Controlled Trials by SUNDY, John S, BARAF, Herbert S. B, HUANG, William, MAROLI, Allan N, WALTRIP, Royce W, HAMBURGER, Steven A, BECKER, Michael A, YOOD, Robert A, EDWARDS, N. Lawrence, GUTIERREZ-URENA, Sergio R, TREADWELL, Edward L, VAZQUEZ-MELLADO, Janitzia, WHITE, William B, LIPSKY, Peter E, HOROWITZ, Zeb

“…Patients with chronic disabling gout refractory to conventional urate-lowering therapy need timely treatment to control disease manifestations related to…”
Get full text

Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy by Baraf, Herbert S B, Becker, Michael A, Gutierrez-Urena, Sergio R, Treadwell, Edward L, Vazquez-Mellado, Janitzia, Rehrig, Claudia D, Ottery, Faith D, Sundy, John S, Yood, Robert A

“…Two replicate randomized, placebo-controlled six-month trials (RCTs) and an open-label treatment extension (OLE) comprised the pegloticase development program…”
Get full text

Adherence with urate-lowering therapies for the treatment of gout by Harrold, Leslie R, Andrade, Susan E, Briesacher, Becky A, Raebel, Marsha A, Fouayzi, Hassan, Yood, Robert A, Ockene, Ira S

“…Adherence to urate-lowering drugs (ULDs) has not been well evaluated among those with gout. Our aim was to assess the level and determinants of non-adherence…”
Get full text

Primary care providers' knowledge, beliefs and treatment practices for gout: results of a physician questionnaire by Harrold, Leslie R, Mazor, Kathleen M, Negron, Amarie, Ogarek, Jessica, Firneno, Cassandra, Yood, Robert A

“…We sought to examine primary care providers' gout knowledge and reported treatment patterns in comparison with current treatment recommendations. We conducted…”
Get full text

Long-term safety of pegloticase in chronic gout refractory to conventional treatment by Becker, Michael A, Baraf, Herbert S B, Yood, Robert A, Dillon, Aileen, Vázquez-Mellado, Janitzia, Ottery, Faith D, Khanna, Dinesh, Sundy, John S

“…To evaluate the long-term safety (up to 3 years) of treatment with pegloticase in patients with refractory chronic gout. This open-label extension (OLE) study…”
Get more information

Serum Procalcitonin in Systemic Autoimmune Diseases—Where Are We Now? by Buhaescu, Irina, MD, Yood, Robert A., MD, Izzedine, Hassan, MD, PhD

“…Objectives To review the current evidence regarding the value of measuring procalcitonin (PCT) levels in patients with systemic autoimmune diseases, with a…”
Get full text

Clinical Characteristics of Early‐Onset Gout in Outpatient Setting by Li, Yan, Piranavan, Paramarajan, Sundaresan, Devi, Yood, Robert

“…Objective The objective of this study is to investigate the clinical characteristics and treatment of patients with early‐onset gout. Methods We…”
Get full text

Effect of pegloticase on renal function in patients with chronic kidney disease: a post hoc subgroup analysis of 2 randomized, placebo-controlled, phase 3 clinical trials by Yood, Robert A, Ottery, Faith D, Irish, William, Wolfson, Marsha

“…Pegloticase is approved in the US for treatment of refractory chronic gout. Since chronic kidney disease (CKD) is common in these patients, we conducted a…”
Get full text

Infusion-Related Reactions With Pegloticase, a Recombinant Uricase for the Treatment of Chronic Gout Refractory to Conventional Therapy by Baraf, Herbert S B, Yood, Robert A, Ottery, Faith D, Sundy, John S, Becker, Michael A

“…BACKGROUNDIn clinical trials of pegloticase, a PEGylated uricase developed for treatment of gout refractory to conventional therapy, infusion-related reactions…”
Get full text

Health plan members' views about disclosure of medical errors by MAZOR, Kathleen M, SIMON, Steven R, YOOD, Robert A, MARTINSON, Brian C, GUNTER, Margaret J, REED, George W, GURWITZ, Jerry H

“…Various authorities and national organizations encourage disclosing medical errors, but there is little information on how patients respond to disclosure. To…”
Get full text

Patient Decision to Initiate Therapy for Osteoporosis: The Influence of Knowledge and Beliefs by Yood, Robert A., Mazor, Kathleen M., Andrade, Susan E., Emani, Srinivas, Chan, Wing, Kahler, Kristijan H.

“…Background There are effective treatments to prevent osteoporotic fractures, but these treatments are underutilized. Objective To evaluate the influence of…”
Get full text

Patients and providers view gout differently: a qualitative study by Harrold, Leslie R., Mazor, Kathleen M., Velten, Sarah, Ockene, Ira S., Yood, Robert A.

“…Objectives: We sought to examine patients’ and providers’ views on the treatment of gout to better understand why management is suboptimal. Methods: In-depth…”
Get full text

Effects of Conjugated Equine Estrogen on Risk of Fractures and BMD in Postmenopausal Women With Hysterectomy: Results From the Women's Health Initiative Randomized Trial by Jackson, Rebecca D, Wactawski‐Wende, Jean, LaCroix, Andrea Z, Pettinger, Mary, Yood, Robert A, Watts, Nelson B, Robbins, John A, Lewis, Cora E, Beresford, Shirley AA, Ko, Marcia G, Naughton, Michelle J, Satterfield, Suzanne, Bassford, Tamsen

“…Further analyses from the Women's Health Initiative estrogen trial shows that CEE reduced fracture risk. The fracture reduction at the hip did not differ…”
Get full text

The Dynamics of Chronic Gout Treatment: Medication Gaps and Return to Therapy by Harrold, Leslie R., MD, MPH, Andrade, Susan E., ScD, Briesacher, Becky, PhD, Raebel, Marsha A., Pharm D, Fouayzi, Hassan, MS, Yood, Robert A., MD, Ockene, Ira S., MD

“…Abstract Objective To identify gaps in therapy with urate-lowering drugs for the treatment of gout as well as factors associated with resuming therapy. Methods…”
Get full text

A Demonstration of the Impact of Response Bias on the Results of Patient Satisfaction Surveys by Mazor, KathleenM, Clauser, BrianE, Field, Terry, Yood, RobertA, Gurwitz, JerryH

“…Objectives. The purposes of the present study were to examine patient satisfaction survey data for evidence of response bias, and to demonstrate, using…”
Get full text

Validation of a surveillance case definition for arthritis by SACKS, JEFFREY J, HARROLD, LESLIE R, HELMICK, CHARLES G, GURWITZ, JERRY H, EMANI, SRINIVAS, YOOD, ROBERT A

“…OBJECTIVE: To assess whether self-reports of chronic joint symptoms or doctor-diagnosed arthritis can validly identify persons with clinically verifiable…”
Get full text

Patients' Perspectives on Plans Generated During Primary Care Visits and Self-Reported Adherence at 3 Months: Data From a Randomized Trial by Stults, Cheryl D, Mazor, Kathleen M, Cheung, Michael, Ruo, Bernice, Li, Martina, Walker, Amanda, Saphirak, Cassandra, Vaida, Florin, Singh, Sonal, Fisher, Kimberly A, Rosen, Rebecca, Yood, Robert, Garber, Lawrence, Longhurst, Christopher, Kallenberg, Gene, Yu, Edward, Chan, Albert, Millen, Marlene, Tai-Seale, Ming

“…Effective primary care necessitates follow-up actions by the patient beyond the visit. Prior research suggests room for improvement in patient adherence. This…”
Get full text

Compliance with pharmacologic therapy for osteoporosis by YOOD, Robert A, EMANI, Srinivas, REED, John I, LEWIS, Barbara Edelman, CHARPENTIER, Mary, LYDICK, Eva

“…There is little information available concerning compliance with pharmacologic therapy for osteoporosis in the usual care setting. We evaluated 176…”
Get full text

Adoption of Once-monthly Oral Bisphosphonates and the Impact on Adherence by Briesacher, Becky A., PhD, Andrade, Susan E., ScD, Harrold, Leslie R., MD, MPH, Fouayzi, Hassan, MS, Yood, Robert A., MD

“…Abstract Background The extent of the adoption of once-monthly bisphosphonates into general clinical practice is not known, nor is it known if the novel…”
Get full text